All News

Best of

#ACR Best 2024 - Day 4

d Jack Cush, MD

Although the last day of ACR Convergence 2024 was but a half day - it was chock full of gems, many coming from the late breaking abstracts presented today.  As chosen by the RheumNow faculty, here are some highlight presentations you need to know about.

Read Article
Say Goodbye to Methotrexate in PMR? Despite mixed results on its clinical efficacy in three previous randomised controlled trials (RCTs)1-3, methotrexate is considered the most widely used GC sparing agent. #ACR24 https://t.co/Q5Sw9dvYqJ https://t.co/jvEmg6aPcq

Links:

Dr. John Cush RheumNow ( View Tweet)
maze-1804499_1280.jpg

Methotrexate to Prevent RA, Clear as Mud

d Richard Conway, MBBChBAO, PhD

Intervention in individuals predisposed to develop RA, with a holy grail of prevention of RA, has long been a hot topic. The 4-year results of the TREAT EARLIER study, presented at Tuesday’s oral abstract session, show that methotrexate appears to prevent the development of RA in high risk ACPA- patients.

Read Article
artificial intelligence machine learning computer

Predicting flares in rheumatic diseases with machine learning

d Antoni Chan, MD, PhD

Rheumatic diseases, such as axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA), are marked by unpredictable disease flares that adversely impact quality of life and long-term outcomes.

Read Article
Prgnancy,outcome

Improving fertility in women with RA

d Jiha Lee, MD

For many women, the journey to motherhood brings a sense of anticipation and joy. However, for those with rheumatoid arthritis, this journey presents unique challenges. At ACR Convergence 2024, researchers discussed how advancements in reproductive medicine and RA management are paving the way for improved outcomes.

Read Article
PsA.Hands_.jpg

Up-front Secukinumab in PsA?

d Richard Conway, MBBChBAO, PhD

We now have an absolute plethora of agents available for use in psoriatic arthritis (PsA). In contrast we have an almost complete lack of understanding of how best to optimise use of these agents – what is the right agent at the right time for the right patient. A study presented this week has given us some further information on the topic.

Read Article
Time the💉 Response to pneumococcal vaccine better when given before starting MTX. Stay updated on ACR and EULAR vaccination recommendations! #ACR24 @RheumNow ABST#2676

Jiha Lee JihaRheum ( View Tweet)

Hypoxia seems to exacerbate neutrophil activation by ANCA - enhanced F-Actin polymerization - enhanced NET formation Could hypoxia predilection in certain tissues (kidney, lung) lead to the AAV phenotypic disease patterns? @RheumNow #ACR24 https://t.co/KxaeMvkd2t

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Increased risk of mortality related to negative effects of GC use persists long after stopping and never return to pre-GC levels. #GCStewardship #ACR24 @RheumNow ABST#2673 https://t.co/5AwHDmvQGf

Links:

Jiha Lee JihaRheum ( View Tweet)
Wt ⬇️ = Better #PROs in 👇autoimmune #rheumatic #diseases if > 5% wt loss. #ACR24 ⁦@ACRheum⁩ ⁦@RheumNow⁩ Didn’t work for non overwt Ex Normal BMI and T2DM 🤷 https://t.co/81OuTfZ0Nx

Links:

Janet Pope Janetbirdope ( View Tweet)
In this study by Dr CArriens et al, there was no difference between the vaccine response to Influenza by either HAI or Ab levels in Anifrolumab-treated pts. AEs - mild, moderate No serious aEs 💉#vaccinate your pts on anifrolumab with influenza @RheumNow #ACR24 abs2424 https://t.co/XPwlzUS02i

Links:

sheila RHEUMarampa ( View Tweet)
Hydralazine - known culprit of drug-induced AAV How does hydral (H) AAV differ from primary (1) AAV? 💥 High dual positivity MPO/PR3 💥 DAH / pleuritis more common in H-AAV 💥 ENT, constitutional, nervous, ILD in 1-AAV 💥 More 6mo remission in H-AAV @rheumnow #ACR24 Abst 2496

Brian Jaros, MD Dr_Brian_MD ( View Tweet)

Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropositivity/shared epitope status. Fits with my priors and refutes a previous pilot study. @RheumNow #ACR24 Abstr#2671 https://t.co/OUwnlsP6jU https://t.co/RBN6ivSKDr

Links:

Richard Conway RichardPAConway ( View Tweet)
Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropositivity/shared epitope status. Fits with my priors and refutes a previous pilot study. @RheumNow #ACR24 Abstr#2671 https://t.co/OUwnlsP6jU https://t.co/RBN6ivSKDr

Links:

Richard Conway RichardPAConway ( View Tweet)
Dumoulin et al. 4 year results of TREAT EARLIER trial of 1 year MTX in CSA. In high risk ACPA- group, reduced risk of RA development, 8.6% vs 29%, HR 0.27. No difference at 4 years in ACPA+ or low risk ACPA- @RheumNow #ACR24 Abstr#2672 #ACRbest https://t.co/S2yJm196UV https://t.co/bJ9JySteUs

Links:

Richard Conway RichardPAConway ( View Tweet)
Dumoulin et al. 4 year results of TREAT EARLIER trial of 1 year MTX in CSA. In high risk ACPA- group, reduced risk of RA development, 8.6% vs 29%, HR 0.27. No difference at 4 years in ACPA+ or low risk ACPA- @RheumNow #ACR24 Abstr#2672 #ACRbest https://t.co/S2yJm196UV https://t.co/bJ9JySteUs

Links:

Richard Conway RichardPAConway ( View Tweet)
SELECT-GCA suggests JAKis may be the new kid on the block Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. https://t.co/vtJzwFZMBq https://t.co/dikMRwjIZY

Links:

Dr. John Cush RheumNow ( View Tweet)
Is Pregnancy Truly the Solution for RA? Pregnancy is perhaps the oldest treatment in rheumatoid arthritis (RA) and has been associated with a natural improvement in disease control in 50-75% of patients. Others, however, are not as successful with unchanged disease activity or… https://t.co/MesVIUl0fC https://t.co/760i5znmeu
Dr. John Cush RheumNow ( View Tweet)
Conaghan et al. LEVI-04, neurotrophin-3 inhibitor in knee OA. 518 patients. Significant improvements in WOMAC pain and function, and PGA. So sign of any increase in rapidly progressive OA (as with NGF inhibitors) @RheumNow #ACR24 Abstr#L15 https://t.co/qud4wTAikY https://t.co/0wjjG4U4bf

Links:

Richard Conway RichardPAConway ( View Tweet)
Conaghan et al. LEVI-04, neurotrophin-3 inhibitor in knee OA. 518 patients. Significant improvements in WOMAC pain and function, and PGA. So sign of any increase in rapidly progressive OA (as with NGF inhibitors) @RheumNow #ACR24 Abstr#L15 https://t.co/qud4wTAikY https://t.co/0wjjG4U4bf

Links:

Richard Conway RichardPAConway ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.